Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Intrinsic Value
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating dis... [ Read More ]
The intrinsic value of one
KNSA
stock under the Base Case scenario is
21.63
USD.
Compared to the current market price of 17.86 USD,
Kiniksa Pharmaceuticals Ltd
is
Undervalued by 17%.
Kiniksa Pharmaceuticals Ltd's market capitalization is 1.3B USD.
KNSA stock price is 17.86 USD.
KNSA stock price (17.86 USD) is 17% less than its Intrinsic Value (21.63 USD).
KNSA stock price (17.86 USD) is 53% less than its Relative Value (37.69 USD). Open Relative Valuation
KNSA has upside potential of 64% compared to the average analyst price target.
Open Wall St Estimates
KNSA's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 7%.
KNSA's Revenue has grown by an exceptional 23% over the past 12 months.
KNSA's ROE (Return on Equity) for the past 12 months is very low and is equal to 3%.
KNSA's ROE (Return on Equity) has significantly increased in the last 3 years from -77% to 3%.
KNSA's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -597% to 7%.
KNSA's Revenue is forecast to grow at a rate of 33% per year over the next 3 years.
KNSA has negative Operating Income for the last twelve months.
KNSA has positive Net Income for the last twelve months.
KNSA has positive Gross Profit for the last twelve months.
KNSA has positive Free Cash Flow for the last twelve months.
KNSA has negative three-year average ROE (Return on Equity): -15%. The company is not efficient at transforming stockholders' equity into net income.
KNSA has negative three-year average ROIC (Return on Invested Capital): -223%. The company is not efficient at using invested capital to generate operating income.
KNSA's short-term assets (276m USD) exceed its short-term liabilties (64m USD).
KNSA's long-term assets (526m USD) exceed its long-term liabilties (87m USD).
KNSA's D/E (Debt to Equity) is very low and is equal to 0.
KNSA's Altman Z-Score is very high and is equal to 7.57.
Valuation Backtest
Kiniksa Pharmaceuticals Ltd
Run backtest to discover the historical profit from buying and selling
KNSA
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Kiniksa Pharmaceuticals Ltd
Balance Sheet Decomposition
Kiniksa Pharmaceuticals Ltd
| Current Assets | 276.3m |
| Cash & Short-Term Investments | 206.4m |
| Receivables | 21.3m |
| Other Current Assets | 48.7m |
| Non-Current Assets | 250m |
| PP&E | 12.7m |
| Intangibles | 17.3m |
| Other Non-Current Assets | 220.1m |
| Current Liabilities | 63.7m |
| Accounts Payable | 8.2m |
| Accrued Liabilities | 46.9m |
| Other Current Liabilities | 8.5m |
| Non-Current Liabilities | 23.8m |
| Other Non-Current Liabilities | 23.8m |
Earnings Waterfall
Kiniksa Pharmaceuticals Ltd
|
Revenue
|
270.3m
USD
|
|
Cost of Revenue
|
-33.4m
USD
|
|
Gross Profit
|
236.9m
USD
|
|
Operating Expenses
|
-262m
USD
|
|
Operating Income
|
-25.2m
USD
|
|
Other Expenses
|
39.3m
USD
|
|
Net Income
|
14.1m
USD
|
Free Cash Flow Analysis
Kiniksa Pharmaceuticals Ltd
KNSA Profitability Score
Profitability Due Diligence
Kiniksa Pharmaceuticals Ltd's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
Kiniksa Pharmaceuticals Ltd's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
KNSA Solvency Score
Solvency Due Diligence
Kiniksa Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Kiniksa Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
KNSA Price Targets Summary
Kiniksa Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for
KNSA
is 29.33 USD
with a low forecast of 25.25 USD and a high forecast of 33.6 USD.
Ownership
KNSA Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
KNSA Price
Kiniksa Pharmaceuticals Ltd
| Average Annual Return | 3% |
| Standard Deviation of Annual Returns | 39.37% |
| Max Drawdown | -71% |
| Market Capitalization | 1.3B USD |
| Shares Outstanding | 70 620 000 |
| Percentage of Shares Shorted | 8.78% |
Company Profile
Kiniksa Pharmaceuticals Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The firm is focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases. The Company’s programs include Rilonacept, which is a protein for inhibiting interleukin-1 alpha and interleukin-1beta; Mavrilimumab, is a monoclonal antibody that antagonizes the signaling of granulocyte macrophage colony stimulating factor, or GM-CSF; KPL-716, is a monoclonal antibody that simultaneously inhibits the signaling of the cytokines interleukin-31, or IL-31, and oncostatin M, or OSM, by targeting their common receptor subunit, oncostatin M receptor beta, or OSMR beta; KPL-045 is a monoclonal antibody inhibitor of the CD30/CD30L interaction, a T-cell co-stimulatory receptor involved in activated T-memory cell function, and KPL-404, is a central control node of T-cell-dependent, B-cell-mediated humoral adaptive immunity.
Contact
IPO
Employees
Officers
The intrinsic value of one
KNSA
stock under the Base Case scenario is
21.63
USD.
Compared to the current market price of 17.86 USD,
Kiniksa Pharmaceuticals Ltd
is
Undervalued by 17%.
You don't have any saved screeners yet
